Y. Liu, C. Dong, X. He, Y. Shu, P. Wu, and J. Zou, “Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System”, J Pharm Pharm Sci, vol. 25, pp. 377–390, Dec. 2022.